H.C. Wainwright


Sorrento Therapeutics Inc (SRNE) Has Competitive Advantage to Claim Meaningful Share in Lidocaine Patch Market, Cheers H.C. Wainwright

Analyst spotlights a compelling commercial future ahead for Sorrento’s ZTlido in post-herpetic neuralgia.

Here’s Why H.C. Wainwright Just Cut the Price Target for Synergy Pharmaceuticals Inc (SGYP) by 50%

Ram Selvaraju slashes his target to $8 on slower Trulance ramp.

Capricor Therapeutics Inc (CAPR) Investors Throw Bullish Parade After H.C. Wainwright Boosts Price Target

Analyst spotlights a compelling path forward for DMD program and looks to key catalysts in fourth quarter.

Just How Frustrated Should Investors Be with Advaxis, Inc. (ADXS)? H.C. Wainwright Remains Bullish

Analyst defends ADXS’ new “astute” clinical development strategy to re-focus on leading product assets.

Rexahn Pharmaceuticals, Inc. (RNN) Phase 2a Update in Muscle Invasive Bladder Cancer Shows Promise, Cheers H.C. Wainwright

RNN’s Phase 2a results have analyst optimistic on RX-3117 drug for patients running out of options.

Ocular Therapeutix Inc (OCUL) Gets A Bullish Vote Following 2Q:17 Update

Ocular Therapeutix Inc (NASDAQ:OCUL) shares are on a roughly 4% dip today after the biotech firm released second-quarter financial results- a quarter that …

Irrational Opioid Crisis Volatility Nipping at AcelRx Pharmaceuticals Inc (ACRX) Presents Stellar Entry Point

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) investors are getting enthusiastic again after the biotech firm’s Phase 3 IAP312 clinical trial of Zalviso, approved in the …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts